Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.
Cox MC, Marcheselli L, Scafetta G, Visco C, Hohaus S, Annibali O, Musuraca G, Fabbri A, Cantonetti M, Pelliccia S, Papotti R, Petrucci L, Tani M, Battistini R, Arcari A, Luminari S, Lopez G, Alma E, Pupo L, Carli G, Marchesi F, Re F, Scarpino S, D'amore ESG, Larocca LM, Bianchi A, Pepe G, Natalino F, Anticoli-Borza P, Cenfra N, Andriani A, Abruzzese E, Tesei C, Leoncini L, Asioli S, Ruco L, Di Napoli A. Cox MC, et al. Among authors: scafetta g. Leukemia. 2022 Nov;36(11):2719-2723. doi: 10.1038/s41375-022-01706-x. Epub 2022 Sep 20. Leukemia. 2022. PMID: 36127510 No abstract available.
IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas.
Di Napoli A, Greco D, Scafetta G, Ascenzi F, Gulino A, Aurisicchio L, Santanelli Di Pompeo F, Bonifacino A, Giarnieri E, Morgan J, Mancini R, Kadin ME. Di Napoli A, et al. Among authors: scafetta g. Cancer Immunol Immunother. 2021 May;70(5):1379-1392. doi: 10.1007/s00262-020-02778-3. Epub 2020 Nov 4. Cancer Immunol Immunother. 2021. PMID: 33146828 Free PMC article.
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
Mazzotta M, Filetti M, Occhipinti M, Marinelli D, Scalera S, Terrenato I, Sperati F, Pallocca M, Rizzo F, Gelibter A, Botticelli A, Scafetta G, Di Napoli A, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Fanciulli M, De Nicola F, Ciuffreda L, Goeman F, De Maria R, Vecchione A, Giusti R, Ciliberto G, Marchetti P, Maugeri-Saccà M. Mazzotta M, et al. Among authors: scafetta g. J Immunother Cancer. 2020 Aug;8(2):e000946. doi: 10.1136/jitc-2020-000946. J Immunother Cancer. 2020. PMID: 32759236 Free PMC article.
B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis.
De Vitis C, D'Ascanio M, Sacconi A, Pizzirusso D, Salvati V, Mancini M, Scafetta G, Cirombella R, Ascenzi F, Bruschini S, Esposito A, Castelli S, Salvucci C, Teodonio L, Sposato B, Catizone A, Di Napoli A, Vecchione A, Ciliberto G, Sciacchitano S, Ricci A, Mancini R. De Vitis C, et al. Among authors: scafetta g. Int J Mol Sci. 2022 Nov 30;23(23):15040. doi: 10.3390/ijms232315040. Int J Mol Sci. 2022. PMID: 36499368 Free PMC article.
Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer.
Peplau E, De Rose F, Reder S, Mittelhäuser M, Scafetta G, Schwaiger M, Weber WA, Bartolazzi A, Skerra A, D'Alessandria C. Peplau E, et al. Among authors: scafetta g. Thyroid. 2020 Sep;30(9):1314-1326. doi: 10.1089/thy.2019.0670. Epub 2020 Apr 30. Thyroid. 2020. PMID: 32200708
Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb.
Varasteh Z, De Rose F, Mohanta S, Li Y, Zhang X, Miritsch B, Scafetta G, Yin C, Sager HB, Glasl S, Gorpas D, Habenicht AJR, Ntziachristos V, Weber WA, Bartolazzi A, Schwaiger M, D'Alessandria C. Varasteh Z, et al. Among authors: scafetta g. Theranostics. 2021 Jan 1;11(4):1864-1876. doi: 10.7150/thno.50247. eCollection 2021. Theranostics. 2021. PMID: 33408786 Free PMC article.
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti F, Nicolis di Robilant V, Ramponi V, Scafetta G, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G, Petroni M. Di Giulio S, et al. Among authors: scafetta g. Oncogene. 2021 Oct;40(43):6143-6152. doi: 10.1038/s41388-021-02003-0. Epub 2021 Sep 10. Oncogene. 2021. PMID: 34508175 Free PMC article.
27 results